Proto Script Pharmaceutical Corp (PSCR) Fair Value & Analysis
Industrials · US · Market cap $9.8K
Proto Script Pharmaceutical Corp
PSCR · US
Strengths
Risks
Fair value as of: Aug 21, 2026
From 2 valuation models · updated yesterday
Below-average quality, currently priced close to our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.
How to read this chart
60‑month range $0.0001 – $0.0160 · the $0.0002 price screens below the $0.0002 fair value. Dashed = 300-day average. As of Aug 21, 2026.
Analysis
Proto Script Pharmaceutical Corp (PSCR) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 27/100 (below-average quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $605K. Revenue grew 17.8% year over year. Fundamentals as of Aug 21, 2026
For context, the median of 10 Industrials peers we cover trades at -22% fair-value upside, at 0%, PSCR screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Widest divergence: DCF Models ($0.0002) versus DCF Models ($0.0002). Highest evidence: Growth DCF (72).
Notify me when PSCR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 30 · Market factors (momentum, volatility) 59
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Proto Script Pharmaceutical Corp. engages in the repair and rental of power wheelchairs and scooters. The company serves federal, state, and private insurance providers. Proto Script Pharmaceutical Corp. was founded in 2001 and is headquartered in Rancho Cucamonga, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2012 – FY2016 · reported fiscal years
Proto Script Pharmaceutical Corp reported revenue of $0 in FY2016 versus $948K in FY2014. Reported net income was −$33.1K in FY2016.
Watch PSCR: get an alert when its fair value changes →
Peer Group
Specialty Business Services · 252 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Business Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Cintas Corporation CTAS | $199.52 | $95.19 | -52% |
| RELX PLC RELX | $34.55 | $32.24 | -7% |
| Thomson Reuters Corporation TRI | C$142.85 | C$70.40 | -51% |
| Copart, Inc CPRT | $28.99 | $28.59 | -1% |
| Global Payments Inc GPN | $88.53 | $68.98 | -22% |
| RB Global, Inc RBA | C$120.52 | C$49.14 | -59% |
| Brambles Limited BXB | A$19.47 | A$17.27 | -11% |
| UL Solutions Inc ULS | $76.68 | $33.62 | -56% |
| ISS A/S ISS | kr 288.20 | kr 251.13 | -13% |
| Xiamen C&D Inc 600153 | ¥8.94 | ¥6.84 | -23% |
Compare Proto Script Pharmaceutical Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Industrials stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Proto Script Pharmaceutical Corp (PSCR) overvalued or undervalued?
What is the fair value of PSCR?
What is the quality score of PSCR?
What is the revenue of Proto Script Pharmaceutical Corp (PSCR)?
What is the net profit margin of PSCR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Proto Script Pharmaceutical Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.